Alterity Therapeutics Ltd has released a press release.
Michael J Fox grant for Parkinsons research on ATH434
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Alterity participates in JP Morgan healthcare conference
- Dr David Stamler Appointed CEO
- Form F-3
- New commercial opportunity for PBT2
- Alterity presents at Finance News Network
Later from Alterity Therapeutics
- Alterity to present at Global Life Science Conference
- ATH434 protects brain cells and improves motor function
- EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial
- New US patent targeting major neurodegenerative diseases
- New Publication Demonstrates ATH434 is Neuroprotective
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics